clinical trial · NCT05756153
A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Advance Non-small Cell Lung CancerGFH925Cetuximab
brief summary
This is a Phase Ib/II study. The objectives are to evaluate the safety/tolerability and efficacy of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC, to characterize pharmacokinetics (PK) of GFH925 in combination with Cetuximab in advanced KRAS G12C mutant NSCLC
started
Apr 25, 2023
primary completion
Apr 30, 2025
completion
Apr 30, 2025
last updated
Aug 12, 2025
official title
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol